Shield Therapeutics has signed a co-promotion and co-marketing agreement with Viatris in the US for Accrufer. STX will receive US$5m upfront and will share revenues 55%/45% with Viatris as both companies equally contribute a 100-person sales force to marketing Accrufer in the US. In addition, STX has announced an additional US$10m convertible bond investment from existing shareholder AOP Health for US$10m and it also plans to raise US$18m (c.£14.7m) in a placing with up to a further £3.9m in an ....
13 Dec 2022
Shield Therapeutics - Viatris deal and a new capital raise transform the outlook
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Viatris deal and a new capital raise transform the outlook
Shield Therapeutics Plc (STX:LON) | 1.3 0 (-7.0%) | Mkt Cap: 10.4m
- Published:
13 Dec 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
13
Shield Therapeutics has signed a co-promotion and co-marketing agreement with Viatris in the US for Accrufer. STX will receive US$5m upfront and will share revenues 55%/45% with Viatris as both companies equally contribute a 100-person sales force to marketing Accrufer in the US. In addition, STX has announced an additional US$10m convertible bond investment from existing shareholder AOP Health for US$10m and it also plans to raise US$18m (c.£14.7m) in a placing with up to a further £3.9m in an ....